The most notable clinical success using ErbB-mAbs leading to FDA approval was accomplished using trastuzumab (Herceptin, 1998, breast cancer targeting HER2) and cetuximab (Erbitux, targeting HER1 or EGFR) which significantly prolonged head and neck squamous cell carcinoma (HNSCC) patient survival (from 29.3 to 49 months) when combined with chemo- (Cisplatin or carboplatin and 5-Fluorouracil) and radiotherapy [58, 59]. The gene discussed is ERBB2; the disease is head and neck squamous cell carcinoma.